Medical Condition

recurrent glioblastoma

Total Trials

13

Recruiting Now

13

Trial Phases

Phase 1, Phase 2, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for recurrent glioblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent glioblastoma Clinical Trials

How many clinical trials are currently recruiting for recurrent glioblastoma?

ClinicalMetric currently tracks 13 actively recruiting clinical trials for recurrent glioblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 13. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for recurrent glioblastoma?

recurrent glioblastoma research spans Phase 1 (10 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a recurrent glioblastoma clinical trial?

Eligibility criteria for recurrent glioblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Beijing Biotech 2 trials

Hideho Okada, MD, PhD 1 trial

Kailin Yang, MD, PhD 1 trial

University of Florida 1 trial

National Cancer Institute (NCI) 1 trial

Recruiting Clinical Trials

NCT06186401 Phase 1

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Hideho Okada, MD, PhD

View Trial →

NCT07541781 Phase 1

Recruiting

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

University of Florida

View Trial →

NCT06344130 Phase 1

Recruiting

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

National Cancer Institute (NCI...

View Trial →

NCT06058988 Phase 2

Recruiting

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Memorial Sloan Kettering Cance...

View Trial →

NCT07480941 Phase 1

Recruiting

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Fifth Affiliated Hospital, Sun...

View Trial →

NCT07193628 Phase 1

Recruiting

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Second Affiliated Hospital, Zh...

View Trial →

NCT07551336 Phase 1

Recruiting

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

NCT07538128 EARLY_Phase 1

Recruiting

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

Mustafa Khasraw, MBChB, MD, FR...

View Trial →

NCT06097975 Phase 1

Recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

Universitair Ziekenhuis Brusse...

View Trial →

NCT05902169 Phase 3

Recruiting

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Enrollment

560 pts

Location

United States, Austr...

Sponsor

CarThera

View Trial →

Related Conditions

glioblastoma (6) glioma (2) malignant glioma (2) egfr gene mutation (1) mgmt unmethylated glioblastoma (1) recurrent glioma (1) grade 4 malignant glioma of brain disorder (1) astrocytoma (1) brain cancer (1) metastatic cancer (1) leptomeningeal metastasis (1) high grade glioma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology